View source for Proton Radiation Therapy

{{TreatmentInfo
|drug_name=Proton Beam Therapy (PBT)
|FDA_approval=Yes
|used_for=Glioblastoma and other cancers
|clinical_trial_phase=Ongoing research and clinical trials
|common_side_effects=Radiation dermatitis, temporary alopecia, radiation otitis, radiation necrosis (more prevalent in PBT group)
|OS_without=Data varies; traditional radiation therapies offer median OS of around 16-21 months for glioblastoma
|OS_with=High-dose PBT showed a median OS of 65.6 months for patients with radiation necrosis, and 26.9 months for patients without radiation necrosis in specific studies
|PFS_without=Standard radiation therapy PFS rates are lower compared to PBT
|PFS_with=Improved PFS observed with PBT, specific rates vary by study
|usefulness_rating=4
|toxicity_level=3
|toxicity_explanation=While acute radiation-related toxicities were equivalent to conventional radiation therapy, PBT has a higher prevalence of radiation necrosis, indicating a need for careful patient selection and management.
|book_text=Proton Beam Therapy (PBT) represents a more targeted form of radiation therapy for glioblastoma, distinguished by its use of protons instead of traditional photons. This method allows for precise targeting of the tumor, minimizing damage to surrounding brain tissue. Research indicates that high-dose PBT can offer significant survival advantages over conventional radiation therapy, although it comes with a higher risk of radiation necrosis. Recent studies have explored the efficacy and safety of PBT, highlighting its potential to improve patient outcomes while also noting the importance of addressing associated toxic...
}}